Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (ONCY)
NASDAQ:ONCY
RESEARCH TOOLSreports
Oncolytics Biotech (ONCY) Stock Price & Analysis
1,087 Followers
ONCY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.88 - $3.39
Previous Close$1.03
Volume325.14K
Average Volume (3M)218.79K
Market Cap
$77.30M
Enterprise Value$52.20M
Total Cash (Recent Filing)C$34.91M
Total Debt (Recent Filing)C$423.00K
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Aug 13, 2024EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding75,853,097
10 Day Avg. Volume177,043
30 Day Avg. Volume218,786
Standard Deviation0.50
R-Squared0.04
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)3.99
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.14Price Target Upside305.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Oncolytics Biotech News
PremiumCompany Announcements
Oncolytics Biotech’s Pelareorep Shows Cancer Therapy Promise
PremiumCompany Announcements
Oncolytics Biotech Shareholders Back Board and Resolutions
PremiumCompany Announcements
Oncolytics Biotech Shareholders Approve Board
PremiumCompany Announcements
Oncolytics Biotech Joins Forces to Battle Pancreatic Cancer
PremiumCompany Announcements
Oncolytics Biotech Joins GCAR for Cancer Trial
PremiumCompany Announcements
Oncolytics Biotech Posts Increased Q1 Loss
PremiumCompany Announcements
Oncolytics Biotech Poised for Pivotal StudiesBulls Say, Bears Say
Bulls Say
Clinical Development ProgressAdvancing toward late-stage clinical development with planned registrational studies in breast and pancreatic cancers.
Collaboration PotentialManagement has expressed optimism regarding a clinical path forward for pelareorep that may include a strategic collaboration with a major biopharmaceutical company.
Market ConfidenceAnalyst maintains a Buy rating and $15 price target on ONCY shares, indicating confidence in Pelareorep's potential success in ongoing and planned trials.
Bears Say
Capital Raising ConcernsPotential dilution risk exists with planned gross equity raises of $100M from 2024E to 2027E.
Financial HealthOncolytics reported 4Q23 results with a net loss of ($2.9M) and ended the period with $25.9M in cash on the balance sheet, which should provide runway into 4Q24.
Investment RisksRisks include clinical development risk tied to pelareorep in multiple tumor types; competitor risk; novel modality risk; reimbursement risk; pricing risk; capital market and dilution risk.
---
Ownership Overview
2.60%
Insiders
0.06% Mutual Funds
0.69% Other Institutional Investors
96.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ONCY FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was $0.88 and its highest was $3.39 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Currently, no data Available
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is Aug 13, 2024 which is in 59 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on May 09, 2024. The company reported -$0.065 earnings per share for the quarter, beating the consensus estimate of -$0.082 by $0.016.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -$0.07.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 75,853,096 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -$0.065 in its last earnings report, beating expectations of -$0.082. Following the earnings report the stock price went down -5.645%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in ONCY
---
Oncolytics Biotech Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.14 (305.88% Upside)
$4.14 (305.88% Upside)
Blogger Sentiment
Bullish
ONCY Sentiment 66%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.75%
12-Months-Change
Fundamentals
Return on Equity
-116.39%
Trailing 12-Months
Asset Growth
-1.63%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
---
ONCY Earnings Call
Q1 2024
0:00 / 0:00
---
ONCY Stock 12 Month Forecast
Average Price Target
$4.14
▲(305.88% Upside)
Technical Analysis
Best Analysts Covering ONCY
1 Year
1 Year Success Rate
7/21 ratings generated profit
1 Year Average Return
-13.35%
assigned a buy rating last month
Copying Douglas Miehm's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -13.35% per trade.
---